

RECEIVED

MAY 08 2002

CERTIFICATE OF MAILING

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name

Cindy Hoang

Signature

Date

4/23/02

11/K.T. 5/9

**AMENDMENT UNDER
37 C.F.R. §1.111**

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket
Confirmation No.

UCSF085CIP
7019

First Named Inventor

NADEL

Application Number

09/616,223

Filing Date

July 14, 2000

Group Art Unit

1635

Examiner Name

J. Zara

Title

PREVENTING AIRWAY MUCUS
PRODUCTION BY
ADMINISTRATION OF EGF-R
ANTAGONISTS

A
W/E.D.T.
I MO

Sir:

This amendment is responsive to the Office Action dated January 2, 2002, for which a three-month period for response was given making this response due on or before April 2, 2002. *A Petition for a one-Month Extension of Time is submitted herewith, making this amendment due on or before May 2, 2002.* Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

I. AMENDMENTS

COPY OF PAPERS
ORIGINALLY FILED

IN THE CLAIMS

Please enter the amendments to claims 1, 17, and 26, as shown below.

1. (Amended) A method of reducing goblet cell hyperplasia in an airway of an individual, comprising:
administering an epidermal growth factor receptor (EGF-R) antagonist that binds the EGF-R to a patient suffering from airway hypersecretion of mucus due to airway goblet cell hyperplasia in an amount effective to reduce goblet cell hyperplasia.

05/06/2002 NMOHAMM1 00000022 500815 09616223

01 FC:115 110.00 CH

17. (Amended) A pharmaceutical formulation for reducing goblet cell hyperplasia in an airway, comprising:
a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist that binds an EGF-R in a dose sufficient to reduce goblet cell hyperplasia in an airway;